Overview

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Alogliptin
Metformin